The intramolecular autoactivation of p38α MAPK is facilitated through TAB1-mediated conformational changes, leading to dual phosphorylation at Thr180/Tyr182 residues independent of canonical MAP2K3/6 activation. #MolecularSignaling
The implications extend beyond cardiac care - this approach could inspire new strategies for other protein-protein interaction targets. #TherapeuticInnovation
Our findings demonstrate that selective pathway inhibition can achieve therapeutic benefits while avoiding traditional side effects. #PharmaceuticalScience
A closer look at the mechanism: TAB1 phosphorylation is nearly abolished in our model, while p38α activation remains largely intact. #MolecularMedicine
Safety finding: Mice with disrupted p38α-TAB1 interaction develop normally, suggesting this approach may have fewer side effects than current treatments. #DrugSafety
🧫 Our crystallography data reveals two key binding sites: a canonical site shared with other proteins and a unique noncanonical site. #StructuralBiology
Technical detail: The binding interface between p38α-TAB1 remains consistent regardless of phosphorylation state - important for drug design. #BiochemResearch
Why this matters: Unlike traditional p38α inhibitors, targeting protein interaction could avoid systemic side effects while maintaining therapeutic benefits. #Therapeutics
Through fragment screening, we identified adamantane compounds that can disrupt p38α-TAB1 binding. A promising start for drug development. #DrugDiscovery
📊 We've solved the X-ray structure of the p38α-TAB1 complex in both active and inactive states, revealing key interaction points for therapeutic targeting. #StructuralBiology
The challenge: Current p38α inhibitors, while effective for cardiac protection, come with significant side effects. Our goal: Find a more selective approach. #Research#DrugDevelopment
🧬 Announcing our research on the p38α-TAB1 pathway: A novel approach to protecting heart tissue during ischemic events through protein-protein interaction studies. #CardiacResearch#Science